Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
14.07
-0.13 (-0.92%)
Nov 4, 2024, 4:00 PM EST - Market closed
Rigel Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 130.2 | 115.78 | 115.74 | 138.74 | 108.62 | 59.29 | Upgrade
|
| Revenue Growth (YoY) | 7.48% | 0.03% | -16.57% | 27.72% | 83.21% | 33.20% | Upgrade
|
| Cost of Revenue | 31.12 | 31.63 | 62.02 | 66.32 | 61 | 53.79 | Upgrade
|
| Gross Profit | 99.08 | 84.15 | 53.72 | 72.42 | 47.63 | 5.5 | Upgrade
|
| Selling, General & Admin | 108.2 | 105.74 | 112.45 | 91.89 | 76.6 | 74.59 | Upgrade
|
| Operating Expenses | 108.2 | 105.74 | 112.45 | 91.89 | 76.6 | 74.59 | Upgrade
|
| Operating Income | -9.12 | -21.59 | -58.73 | -19.48 | -28.97 | -69.09 | Upgrade
|
| Interest Expense | -7.71 | -6.87 | -3.71 | -4.86 | -1.35 | -0.34 | Upgrade
|
| Interest & Investment Income | 2.5 | 2.27 | 0.68 | 0.05 | 0.58 | 2.53 | Upgrade
|
| EBT Excluding Unusual Items | -14.33 | -26.19 | -61.75 | -24.29 | -29.74 | -66.89 | Upgrade
|
| Merger & Restructuring Charges | - | - | -1.32 | -3.52 | - | - | Upgrade
|
| Other Unusual Items | 0.1 | 1.1 | 4.5 | 10.5 | - | - | Upgrade
|
| Pretax Income | -14.23 | -25.09 | -58.57 | -17.31 | -29.74 | -66.89 | Upgrade
|
| Income Tax Expense | - | - | - | 0.61 | - | - | Upgrade
|
| Net Income | -14.23 | -25.09 | -58.57 | -17.91 | -29.74 | -66.89 | Upgrade
|
| Net Income to Common | -14.23 | -25.09 | -58.57 | -17.91 | -29.74 | -66.89 | Upgrade
|
| Shares Outstanding (Basic) | 17 | 17 | 17 | 17 | 17 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 17 | 17 | 17 | 17 | 17 | Upgrade
|
| Shares Change (YoY) | 0.93% | 0.93% | 1.12% | 1.03% | 0.81% | 4.28% | Upgrade
|
| EPS (Basic) | -0.81 | -1.44 | -3.40 | -1.05 | -1.76 | -4.00 | Upgrade
|
| EPS (Diluted) | -0.81 | -1.44 | -3.40 | -1.05 | -1.76 | -4.00 | Upgrade
|
| Free Cash Flow | -12.31 | -5.74 | -74.21 | 5.25 | -53.45 | -42.97 | Upgrade
|
| Free Cash Flow Per Share | -0.70 | -0.33 | -4.30 | 0.31 | -3.17 | -2.57 | Upgrade
|
| Gross Margin | 76.10% | 72.68% | 46.41% | 52.20% | 43.85% | 9.27% | Upgrade
|
| Operating Margin | -7.00% | -18.65% | -50.74% | -14.04% | -26.67% | -116.53% | Upgrade
|
| Profit Margin | -10.93% | -21.67% | -50.61% | -12.91% | -27.38% | -112.83% | Upgrade
|
| Free Cash Flow Margin | -9.45% | -4.96% | -64.12% | 3.78% | -49.21% | -72.47% | Upgrade
|
| EBITDA | -7.52 | -20.35 | -57.73 | -18.31 | -28.27 | -68.41 | Upgrade
|
| EBITDA Margin | -5.78% | -17.58% | -49.88% | -13.20% | -26.02% | -115.38% | Upgrade
|
| D&A For EBITDA | 1.6 | 1.24 | 1 | 1.16 | 0.71 | 0.68 | Upgrade
|
| EBIT | -9.12 | -21.59 | -58.73 | -19.48 | -28.97 | -69.09 | Upgrade
|
| EBIT Margin | -7.00% | -18.65% | -50.74% | -14.04% | -26.67% | -116.53% | Upgrade
|
| Revenue as Reported | 130.3 | 116.88 | 120.24 | 149.24 | 108.62 | 59.29 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.